Analytical Data
-
Gene name
VACWR074
- Application
-
Alternative Names
Protein VP13K
-
Species
Vaccinia virus
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12924
-
Expression Region
2-79aa
-
Molecular Weight
24.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VACWR074 recombinant protein, derived from the vaccinia virus, has garnered attention due to its potential applications in both vaccine development and therapeutic interventions. Vaccinia virus, a member of the Poxviridae family, has been extensively studied for its unique ability to stimulate robust immune responses, making it an ideal candidate for vaccine platforms. The VACWR074 gene encodes a protein that plays a critical role in the virus's life cycle and immune evasion mechanisms. Understanding the structure and function of VACWR074 could unveil new insights into viral pathogenesis and host immune interactions. Moreover, harnessing this recombinant protein could pave the way for developing innovative vaccines against various infectious diseases, including those caused by other members of the Poxviridae family. Research efforts are focused on characterizing the immunogenicity of VACWR074, evaluating its potential as an adjuvant, and exploring its role in modulating both innate and adaptive immunity. By eliminating traditional vaccine development hurdles, VACWR074 may offer a promising avenue for enhanced protection strategies, ultimately contributing to global health initiatives against viral infections.
